Ribonuclease H inhibitors: Structural and molecular biology

Human Immunodeficiency Virus Reverse Transcriptase: A Bench-to-Bedside Success

Volumn , Issue , 2013, Pages 143-172

  Rausch, Jason W ^a  

^a FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84902502321     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-7291-9_7     Document Type: Chapter

References (86)

1. Allen SJW, Krawczyk SH, McGee LR, Bischofberger N, Mulato AS, Cherrington JM (1996) Inhibition of HIV-1 RNase H activity by nucleotide dimers and monomers. Antivir Chem Chemother 7(1):37-45
2. Arion D, Sluis-Cremer N, Min KL, Abram ME, Fletcher RS, Parniak MA (2002) Mutational analysis of Tyr-501 of HIV-1 reverse transcriptase. Effects on ribonuclease H activity and inhibition of this activity by N-acylhydrazones. J Biol Chem 277(2):1370-1374
3. Asahchop EL, Wainberg MA, Sloan RD, Tremblay CL (2012) Antiviral drug resistance and the need for development of new HIV-1 reverse transcriptase inhibitors. Antimicrob Agents Chemother. doi: 10.1128/AAC.00591-12
4. Beilhartz GL, Wendeler M, Baichoo N, Rausch J, Le Grice S, Gotte M (2009) HIV-1 reverse transcriptase can simultaneously engage its DNA/RNA substrate at both DNA polymerase and RNase H active sites: implications for RNase H inhibition. J Mol Biol 388(3):462-474
5. Borkow G, Fletcher RS, Barnard J, Arion D, Motakis D, Dmitrienko GI, Parniak MA (1997) Inhibition of the ribonuclease H and DNA polymerase activities of HIV-1 reverse transcriptase by N-(4-tert-butylbenzoyl)-2-hydroxy-1-naphthaldehyde hydrazone. Biochemistry 36(11): 3179-3185
6. Budihas SR, Gorshkova I, Gaidamakov S, Wamiru A, Bona MK, Parniak MA et al (2005) Selective inhibition of HIV-1 reverse transcriptase-associated ribonuclease H activity by hydroxylated tropolones. Nucleic Acids Res 33(4):1249-1256
7. Champoux JJ, Schultz SJ (2009) Ribonuclease H: properties, substrate specificity and roles in retroviral reverse transcription. FEBS J 276(6):1506-1516. doi: 10.1111/j.1742-4658.2009.06909.x
8. Chung S, Wendeler M, Rausch JW, Beilhartz G, Gotte M, O'Keefe BR et al (2010) Structure-activity analysis of vinylogous urea inhibitors of human immunodeficiency virus-encoded ribonuclease H. Antimicrob Agents Chemother 54(9):3913-3921. doi: 10.1128/AAC.00434-10
9. Chung S, Himmel DM, Jiang JK, Wojtak K, Bauman JD, Rausch JW et al (2011) Synthesis, activity, and structural analysis of novel alpha-hydroxytropolone inhibitors of human immunodeficiency virus reverse transcriptase-associated ribonuclease H. J Med Chem 54(13):4462-4473. doi: 10.1021/jm2000757
10. Chung S, Miller JT, Johnson BC, Hughes SH, Le Grice SF (2012) Mutagenesis of human immunodeficiency virus reverse transcriptase p51 subunit defines residues contributing to vinylogous urea inhibition of ribonuclease H activity. J Biol Chem 287(6):4066-4075. doi: 10.1074/jbc.M111.314781
11. Cirino NM, Kalayjian RC, Jentoft JE, Le Grice SF (1993) Fluorimetric analysis of recombinant p15 HIV-1 ribonuclease H. J Biol Chem 268(20):14743-14749
12. Cowan JA, Ohyama T, Howard K, Rausch JW, Cowan SM, Le Grice SF (2000) Metal-ion stoichiometry of the HIV-1 RT ribonuclease H domain: evidence for two mutually exclusive sites leads to new mechanistic insights on metal-mediated hydrolysis in nucleic acid biochemistry. J Biol Inorg Chem JBIC A Publ Soc Biol Inorg Chem 5(1):67-74
13. Curran DP, Parniak MA, Gabarda A (2004) USA Patent no. US 2004/0058948 A1. United States Patent Application Publication: U. S. P. Office
14. Das D, Georgiadis MM (2004) The crystal structure of the monomeric reverse transcriptase from Moloney murine leukemia virus. Structure 12(5):819-829. doi: 10.1016/j.str.2004.02.032
15. Das K, Bauman JD, Clark AD Jr, Frenkel YV, Lewi PJ, Shatkin AJ et al (2008) High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: strategic flexibility explains potency against resistance mutations. Proc Natl Acad Sci USA 105(5):1466-1471. doi: 10.1073/pnas.0711209105
16. Das K, Martinez SE, Bauman JD, Arnold E (2012) HIV-1 reverse transcriptase complex with DNA and nevirapine reveals non-nucleoside inhibition mechanism. Nat Struct Mol Biol 19(2):253-259. doi: 10.1038/nsmb.2223
17. Davies JF 2nd, Hostomska Z, Hostomsky Z, Jordan SR, Matthews DA (1991) Crystal structure of the ribonuclease H domain of HIV-1 reverse transcriptase. Science 252(5002):88-95
18. Davis CA, Parniak MA, Hughes SH (2011) The effects of RNase H inhibitors and nevirapine on the susceptibility of HIV-1 to AZT and 3TC. Virology 419(2):64-71. doi: 10.1016/j.virol.2011.08.010
19. De Clercq E (2009) Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. Int J Antimicrob Agents 33(4):307-320. doi: 10.1016/j.ijantimicag.2008.10.010
20. Delviks-Frankenberry KA, Nikolenko GN, Barr R, Pathak VK (2007) Mutations in human immunodeficiency virus type 1 RNase H primer grip enhance 3′-azido-3′-deoxythymidine resistance. J Virol 81(13):6837-6845
21. Delviks-Frankenberry KA, Nikolenko GN, Boyer PL, Hughes SH, Coffin JM, Jere A, Pathak VK (2008) HIV-1 reverse transcriptase connection subdomain mutations reduce template RNA degradation and enhance AZT excision. Proc Natl Acad Sci USA 105(31):10943-10948. doi: 10.1073/pnas.0804660105.
22. Delviks-Frankenberry KA, Nikolenko GN, Pathak VK (2010) The "connection" between HIV drug resistance and RNase H. Viruses 2(7):1476-1503. doi: 10.3390/v2071476
23. DeStefano JJ, Bambara RA, Fay PJ (1993) Parameters that influence the binding of human immunodeficiency virus reverse transcriptase to nucleic acid structures. Biochemistry 32(27): 6908-6915
24. Di Grandi M, Olson M, Prashad AS, Bebernitz G, Luckay A, Mullen S et al (2010) Small molecule inhibitors of HIV RT Ribonuclease H. Bioorg Med Chem Lett 20(1):398-402. doi: 10.1016/j.bmcl.2009.10.043
25. Di Marzo Veronese F, Copeland TD, DeVico AL, Rahman R, Oroszlan S, Gallo RC, Sarngadharan MG (1986) Characterization of highly immunogenic p66/p51 as the reverse transcriptase of HTLV-III/LAV. Science (Washington, DC 1883-) 231(4743):1289-1291
26. Ehteshami M, Beilhartz GL, Scarth BJ, Tchesnokov EP, McCormick S, Wynhoven B et al (2008) Connection domain mutations N348I and A360V in HIV-1 reverse transcriptase enhance resistance to 3′-azido-3′-deoxythymidine through both RNase H-dependent and -independent mechanisms. J Biol Chem 283(32):22222-22232
27. Furfine ES, Reardon JE (1991) Reverse transcriptase. RNase H from the human immunodeficiency virus. Relationship of the DNA polymerase and RNA hydrolysis activities. J Biol Chem 266(1):406-412
28. Gabbara S, Davis WR, Hupe L, Hupe D, Peliska JA (1999) Inhibitors of DNA strand transfer reactions catalyzed by HIV-1 reverse transcriptase. Biochemistry 38(40):13070-13076
29. Gotte M, Fackler S, Hermann T, Perola E, Cellai L, Gross HJ et al (1995) HIV-1 reverse transcriptase-associated RNase H cleaves RNA/RNA in arrested complexes: implications for the mechanism by which RNase H discriminates between RNA/RNA and RNA/DNA. EMBO J 14(4):833-841
30. Gotte M, Maier G, Gross HJ, Heumann H (1998) Localization of the active site of HIV-1 reverse transcriptase-associated RNase H domain on a DNA template using site-specific generated hydroxyl radicals. J Biol Chem 273(17):10139-10146
31. Gotte M, Rausch JW, Marchand B, Sarafianos S, Le Grice SF (2010) Reverse transcriptase in motion: conformational dynamics of enzyme-substrate interactions. Biochim Biophys Acta 1804(5):1202-1212. doi: 10.1016/j.bbapap.2009.07.020
32. Hang JQ, Rajendran S, Yang Y, Li Y, In PW, Overton H et al (2004) Activity of the isolated HIV RNase H domain and specific inhibition by N-hydroxyimides. Biochem Biophys Res Commun 317(2):321-329
33. Hang JQ, Li Y, Yang Y, Cammack N, Mirzadegan T, Klumpp K (2007) Substrate-dependent inhibition or stimulation of HIV RNase H activity by non-nucleoside reverse transcriptase inhibitors (NNRTIs). Biochem Biophys Res Commun 352(2):341-350
34. Hansen J, Schulze T, Mellert W, Moelling K (1988) Identification and characterization of HIVspecific RNase H by monoclonal antibody. EMBO J 7(1):239-243
35. Hare S, Vos AM, Clayton RF, Thuring JW, Cummings MD, Cherepanov P (2010) Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance. [Research support, Non-U.S. Gov't]. Proc Natl Acad Sci USA 107(46):20057-20062. doi: 10.1073/pnas.1010246107
36. Hazuda DJ, Felock P, Witmer M, Wolfe A, Stillmock K, Grobler JA et al (2000) Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 287(5453):646-650
37. Himmel DM, Sarafianos SG, Dharmasena S, Hossain MM, McCoy-Simandle K, Ilina T et al (2006) HIV-1 reverse transcriptase structure with RNase H inhibitor dihydroxy benzoyl naphthyl hydrazone bound at a novel site. ACS Chem Biol 1(11):702-712
38. Himmel DM, Maegley KA, Pauly TA, Bauman JD, Das K, Dharia C et al (2009) Structure of HIV-1 reverse transcriptase with the inhibitor beta-Thujaplicinol bound at the RNase H active site. Structure 17(12):1625-1635
39. Huang H, Chopra R, Verdine GL, Harrison SC (1998) Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. Science 282(5394): 1669-1675
40. Jacobo-Molina A, Ding J, Nanni RG, Clark AD Jr, Lu X, Tantillo C et al (1993) Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA. Proc Natl Acad Sci USA 90(13):6320-6324
41. Katayanagi K, Miyagawa M, Matsushima M, Ishikawa M, Kanaya S, Ikehara M et al (1990) Three-dimensional structure of ribonuclease H from E. coli. Nature 347(6290):306-309
42. Keck JL, Marqusee S (1995) Substitution of a highly basic helix/loop sequence into the RNase H domain of human immunodeficiency virus reverse transcriptase restores its Mn(2+)-dependent RNase H activity. Proc Natl Acad Sci USA 92(7):2740-2744
43. Keck JL, Goedken ER, Marqusee S (1998) Activation/attenuation model for RNase H. A onemetal mechanism with second-metal inhibition. J Biol Chem 273(51):34128-34133
44. Kirschberg TA, Balakrishnan M, Squires NH, Barnes T, Brendza KM, Chen X et al (2009) RNase H active site inhibitors of human immunodeficiency virus type 1 reverse transcriptase: design, biochemical activity, and structural information. J Med Chem 52(19):5781-5784. doi: 10.1021/jm900597q
45. Klumpp K, Mirzadegan T (2006) Recent progress in the design of small molecule inhibitors of HIV RNase H. Curr Pharm Des 12(15):1909-1922
46. Klumpp K, Hang JQ, Rajendran S, Yang Y, Derosier A, Wong Kai In P et al (2003) Two-metal ion mechanism of RNA cleavage by HIV RNase H and mechanism-based design of selective HIV RNase H inhibitors. Nucleic Acids Res 31(23):6852-6859
47. Kohlstaedt LA, Wang J, Friedman JM, Rice PA, Steitz TA (1992) Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 256(5065): 1783-1790
48. Lansdon EB, Liu Q, Leavitt SA, Balakrishnan M, Perry JK, Lancaster-Moyer C et al (2011) Structural and binding analysis of pyrimidinol carboxylic acid and N-hydroxy quinazolinedione HIV-1 RNase H inhibitors. Antimicrob Agents Chemother 55(6):2905-2915. doi: 10.1128/AAC.01594-10
49. Loya S, Hizi A (1990) The inhibition of human immunodeficiency virus type 1 reverse transcriptase by avarol and avarone derivatives. FEBS Lett 269(1):131-134
50. Loya S, Hizi A (1993) The interaction of illimaquinone, a selective inhibitor of the RNase H activity, with the reverse transcriptases of human immunodeficiency and murine leukemia retroviruses. J Biol Chem 268(13):9323-9328
51. Loya S, Tal R, Kashman Y, Hizi A (1990) Illimaquinone, a selective inhibitor of the RNase H activity of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 34(10):2009-2012
52. Ma JB, Yuan YR, Meister G, Pei Y, Tuschl T, Patel DJ (2005) Structural basis for 5′-end-specific recognition of guide RNA by the A. fulgidus Piwi protein. Nature 434(7033):666-670
53. Min BS, Miyashiro H, Hattori M (2002) Inhibitory effects of quinones on RNase H activity associated with HIV-1 reverse transcriptase. Phytother Res PTR 16(Suppl 1):S57-S62
54. Nikolenko GN, Delviks-Frankenberry KA, Palmer S, Maldarelli F, Fivash MJ Jr, Coffin JM, Pathak VK (2007) Mutations in the connection domain of HIV-1 reverse transcriptase increase 3′-azido-3′-deoxythymidine resistance. Proc Natl Acad Sci USA 104(1):317-322
55. Nowotny M (2009) Retroviral integrase superfamily: the structural perspective. EMBO Rep 10(2):144-151. doi: 10.1038/embor.2008.256
56. Nowotny M, Gaidamakov SA, Crouch RJ, Yang W (2005) Crystal structures of RNase H bound to an RNA/DNA hybrid: substrate specificity and metal-dependent catalysis. Cell 121(7):1005-1016
57. Nowotny M, Gaidamakov SA, Ghirlando R, Cerritelli SM, Crouch RJ, Yang W (2007) Structure of human RNase H1 complexed with an RNA/DNA hybrid: insight into HIV reverse transcription. Mol Cell 28(2):264-276
58. Palaniappan C, Fuentes GM, Rodriguez-Rodriguez L, Fay PJ, Bambara RA (1996) Helix structure and ends of RNA/DNA hybrids direct the cleavage specificity of HIV-1 reverse transcriptase RNase H. J Biol Chem 271(4):2063-2070
59. Parkes KE, Ermert P, Fassler J, Ives J, Martin JA, Merrett JH et al (2003) Use of a pharmacophore model to discover a new class of influenza endonuclease inhibitors. J Med Chem 46(7): 1153-1164
60. Parniak MA, Min KL, Budihas SR, Le Grice SF, Beutler JA (2003) A fluorescence-based highthroughput screening assay for inhibitors of human immunodeficiency virus-1 reverse transcriptase-associated ribonuclease H activity. Anal Biochem 322(1):33-39. doi: 10.1016/j.ab.2003.06.001
61. Peliska JA, Benkovic SJ (1992) Mechanism of DNA strand transfer reactions catalyzed by HIV-1 reverse transcriptase. [Research Support, U.S. Gov't, P.H.S.]. Science 258(5085):1112-1118
62. Rausch JW, Le Grice SF (2004) 'Binding, bending and bonding': polypurine tract-primed initiation of plus-strand DNA synthesis in human immunodeficiency virus. Int J Biochem Cell Biol 36(9):1752-1766. doi: 10.1016/j.biocel.2004.02.016
63. Ren J, Nichols C, Bird L, Chamberlain P, Weaver K, Short S et al (2001) Structural mechanisms of drug resistance for mutations at codons 181 and 188 in HIV-1 reverse transcriptase and the improved resilience of second generation non-nucleoside inhibitors. J Mol Biol 312(4):795-805. doi: 10.1006/jmbi.2001.4988
64. Rodgers DW, Gamblin SJ, Harris BA, Ray S, Culp JS, Hellmig B et al (1995) The structure of unliganded reverse transcriptase from the human immunodeficiency virus type 1. Proc Natl Acad Sci USA 92(4):1222-1226
65. Rothwell PJ, Waksman G (2005) Structure and mechanism of DNA polymerases. Adv Protein Chem 71:401-440. doi: 10.1016/S0065-3233(04)71011-6
66. Ruane PJ, DeJesus E (2004) New nucleoside/nucleotide backbone options: a review of recent studies. J Acquir Immune Defic Syndr 37(Suppl 1):S21-S29
67. Sarafianos SG, Das K, Tantillo C, Clark AD Jr, Ding J, Whitcomb JM et al (2001) Crystal structure of HIV-1 reverse transcriptase in complex with a polypurine tract RNA:DNA. EMBO J 20(6):1449-1461
68. Schatz O, Cromme FV, Gruninger-Leitch F, Le Grice SF (1989) Point mutations in conserved amino acid residues within the C-terminal domain of HIV-1 reverse transcriptase specifically repress RNase H function. FEBS Lett 257(2):311-314
69. Schultz SJ, Champoux JJ (2008) RNase H activity: structure, specificity, and function in reverse transcription. Virus Res 134(1-2):86-103. doi: 10.1016/j.virusres.2007.12.007
70. Schultz SJ, Zhang M, Champoux JJ (2004) Recognition of internal cleavage sites by retroviral RNases H. J Mol Biol 344(3):635-652. doi: 10.1016/j.jmb.2004.09.081
71. Shaw-Reid CA, Munshi V, Graham P, Wolfe A, Witmer M, Danzeisen R et al (2003) Inhibition of HIV-1 ribonuclease H by a novel diketo acid, 4-[5-(benzoylamino)thien-2-yl]-2,4-dioxobutanoic acid. J Biol Chem 278(5):2777-2780. doi: 10.1074/jbc.C200621200
72. Shaw-Reid CA, Feuston B, Munshi V, Getty K, Krueger J, Hazuda DJ et al (2005) Dissecting the effects of DNA polymerase and ribonuclease H inhibitor combinations on HIV-1 reversetranscriptase activities. Biochemistry 44(5):1595-1606. doi: 10.1021/bi0486740
73. Shih CK, Rose JM, Hansen GL, Wu JC, Bacolla A, Griffin JA (1991) Chimeric human immunodeficiency virus type 1/type 2 reverse transcriptases display reversed sensitivity to nonnucleoside analog inhibitors. Proc Natl Acad Sci USA 88(21):9878-9882
74. Sluis-Cremer N, Arion D, Parniak MA (2000) Molecular mechanisms of HIV-1 resistance to nucleoside reverse transcriptase inhibitors (NRTIs). Cell Mol Life Sci CMLS 57(10): 1408-1422
75. Sluis-Cremer N, Arion D, Parniak MA (2002) Destabilization of the HIV-1 reverse transcriptase dimer upon interaction with N-acyl hydrazone inhibitors. Mol Pharmacol 62(2):398-405
76. Song JJ, Smith SK, Hannon GJ, Joshua-Tor L (2004) Crystal structure of argonaute and its implications for RISC slicer activity. Science 305(5689):1434-1437
77. Stahl SJ, Kaufman JD, Vikic-Topic S, Crouch RJ, Wingfield PT (1994) Construction of an enzymatically active ribonuclease H domain of human immunodeficiency virus type 1 reverse transcriptase. Protein Eng 7(9):1103-1108
78. Summa V, Petrocchi A, Pace P, Matassa VG, De Francesco R, Altamura S et al (2004) Discovery of alpha, gamma-diketo acids as potent selective and reversible inhibitors of hepatitis C virus NS5b RNA-dependent RNA polymerase. J Med Chem 47(1):14-17. doi: 10.1021/jm0342109
79. Tan CK, Civil R, Mian AM, So AG, Downey KM (1991) Inhibition of the RNase H activity of HIV reverse transcriptase by azidothymidylate. Biochemistry 30(20):4831-4835
80. Telesnitsky A, Goff SP (1997) Reverse transcriptase and the generation of retroviral DNA. In: Coffin JM, Hughes SH, Varmus HE (eds) Retroviruses. Cold Spring Harbor Laboratory Press, Plainview, pp. 121-160
81. Tomassini J, Selnick H, Davies ME, Armstrong ME, Baldwin J, Bourgeois M et al (1994) Inhibition of cap (m7GpppXm)-dependent endonuclease of influenza virus by 4-substituted 2,4-dioxobutanoic acid compounds. Antimicrob Agents Chemother 38(12):2827-2837
82. Tramontano E, Esposito F, Badas R, Di Santo R, Costi R, La Colla P (2005) 6-[1-(4-Fluorophenyl) methyl-1H-pyrrol-2-yl)]-2,4-dioxo-5-hexenoic acid ethyl ester a novel diketo acid derivative which selectively inhibits the HIV-1 viral replication in cell culture and the ribonuclease H activity in vitro. Antiviral Res 65(2):117-124
83. Tsunaka Y, Haruki M, Morikawa M, Oobatake M, Kanaya S (2003) Dispensability of glutamic acid 48 and aspartic acid 134 for Mn2+-dependent activity of E. coli ribonuclease HI. Biochemistry 42(11):3366-3374. doi: 10.1021/bi0205606
84. Tsunaka Y, Takano K, Matsumura H, Yamagata Y, Kanaya S (2005) Identification of single Mn(2+) binding sites required for activation of the mutant proteins of E. coli RNase HI at Glu48 and/or Asp134 by X-ray crystallography. J Mol Biol 345(5):1171-1183
85. Wendeler M, Lee HF, Bermingham A, Miller JT, Chertov O, Bona MK et al (2008) Vinylogous ureas as a novel class of inhibitors of reverse transcriptase-associated ribonuclease H activity. ACS Chem Biol 3(10):635-644
86. Zhan X, Tan CK, Scott WA, Mian AM, Downey KM, So AG (1994) Catalytically distinct conformations of the ribonuclease H of HIV-1 reverse transcriptase by substrate cleavage patterns and inhibition by azidothymidylate and N-ethylmaleimide. Biochemistry 33(6):1366-1372